{"id":648266,"date":"2023-04-20T17:10:03","date_gmt":"2023-04-20T17:10:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=648266"},"modified":"2023-04-20T17:10:03","modified_gmt":"2023-04-20T17:10:03","slug":"botulism-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-xoma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/botulism-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-xoma-and-others_648266.html","title":{"rendered":"Botulism Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies – XOMA, and others"},"content":{"rendered":"
\n
\"Botulism<\/a><\/div>\n
\n
Botulism Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Botulism – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Botulism, historical and forecasted epidemiology as well as the Botulism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Botulism – Market Insights, Epidemiology, and Market Forecast-2032<\/a>”.<\/strong><\/p>\n

DelveInsight’s “Botulism – Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>″ report delivers an in-depth understanding of the Botulism, historical and forecasted epidemiology as well as the Botulism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Botulism Market Report:<\/strong><\/p>\n

    \n
  1. According to the Centers for Disease Control and Prevention (CDC), about 145 cases of botulism are reported every year in the United States. About 3 to 5 percent of those with botulism poisoning die.<\/li>\n
  2. Also, CDC reports that 65 percent of botulism cases occur in infants or children younger than 1 year of age. Around 15 percent of botulism cases are foodborne.<\/li>\n
  3. According to National Botulism Surveillance Summary (2017), 182 laboratory-confirmed botulism cases were reported to CDC in 2017—141 (77%) infant, 19 (10%) foodborne, 19 (10%) wound, and three (1%) “other” classified as two (1%) iatrogenic, and one (1%) suspected adult intestinal colonization<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. Botulism market report covers a descriptive overview and comprehensive insight of the Botulism Epidemiology and Botulism  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. The Botulism market report provides insights on the current and emerging therapies.<\/li>\n
    3. Botulism market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n
    4. The Botulism market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Botulism market.<\/li>\n<\/ol>\n

      Got queries? Click here to know more about the Botulism Market Landscape<\/a>.<\/strong><\/p>\n

      Botulism Overview<\/strong><\/p>\n

      Botulism (or botulism poisoning) is a rare but very serious illness that transmits through food, contact with contaminated soil, or through an open wound. Without early treatment, botulism can lead to paralysis, breathing difficulties, and death. There are three main types of botulism: infant botulism, foodborne botulism, and wound botulism. Botulism poisoning is due to a toxin produced by a type of bacteria called Clostridium botulinum. Although very common, these bacteria can only thrive in conditions where there’s no oxygen. Certain food sources, such as home-canned foods, provide a potent breeding ground.<\/p>\n

      Botulism Market <\/p>\n

      The dynamics of the Botulism market<\/a><\/strong> are anticipated to change in the coming years owing to the expected launch of emerging therapies such as XOMA, and others during the forecasted period 2019-2032.<\/p>\n

      Botulism Pipeline Therapies and Key Companies <\/strong><\/p>\n